151. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients
- Author
-
Chrystia M. Zobniw, Neeta Somaiah, Shreyaskumar Patel, Gustavo Schvartsman, Van Anh Trinh, and Michael J. Wagner
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Pathology ,Gastrointestinal Stromal Tumors ,Pyridines ,medicine.medical_treatment ,Targeted therapy ,03 medical and health sciences ,chemistry.chemical_compound ,Fatal Outcome ,0302 clinical medicine ,Central retinal vein occlusion ,Internal medicine ,Regorafenib ,Retinal Vein Occlusion ,medicine ,Humans ,Stromal tumor ,Protein Kinase Inhibitors ,neoplasms ,Aged ,Gastrointestinal Neoplasms ,GiST ,business.industry ,Phenylurea Compounds ,Imatinib ,medicine.disease ,digestive system diseases ,Proto-Oncogene Proteins c-kit ,030104 developmental biology ,Imatinib mesylate ,chemistry ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Sarcoma ,business ,medicine.drug - Abstract
Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract with around 5000 new cases per year. Outcomes for patients with GIST dramatically improved after the development of tyrosine kinase inhibitors targeted against the aberrant signaling pathways that drive GIST oncogenesis. Majority of patients derive benefit from first-line imatinib, and the type of driver mutation is predictive of response. However, almost half of the patients eventually develop resistance to initial targeted therapy and further lines of treatment do not have the same impact. Regorafenib is an oral multi-kinase inhibitor approved as a third-line therapy for advanced GIST and though its efficacy is limited in comparison to imatinib, it has activity across the various driver mutation categories in GIST even in the setting of imatinib resistance. Herein, we describe a case of central retinal vein occlusion (CRVO) secondary to regorafenib and review regorafenib's efficacy and toxicity profile.
- Published
- 2016